Samuel Gonzalez Rodriguez
Hematology & Oncology · Guayama, PRNPI 1861474223
Payments from drug & device makers
Across 318 payments — averaging $21.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$894
- Merck$763
- Novartis$564
- Pfizer$453
- Lilly USA, LLC$350
- plus $3K from 36 others
What the payments were for
- Food & beverage$6,23292%
- Education$5728%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$115
- WATCHMAN Access System$104
How this compares
$6,804 in reported general payments places this provider in the 35th percentile of 138 hematology & oncology providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 135 | $3,004,426 |
| IbrancePalbociclib | 64 | $1,015,300 |
| SprycelDasatinib | 54 | $677,356 |
| ErleadaApalutamide | 43 | $644,484 |
| KeytrudaPembrolizumab | 43 | $585,782 |
| VerzenioAbemaciclib | 22 | $332,658 |
| InlytaAxitinib | 16 | $332,360 |
| ImbruvicaIbrutinib | 15 | $246,995 |
| XtandiEnzalutamide | 13 | $186,182 |
| ZepzelcaLurbinectedin | 11 | $183,907 |
| EliquisApixaban | 37 | $22,080 |
| Everolimus | 13 | $19,141 |
| Abiraterone Acetate | 50 | $16,617 |
| Imatinib Mesylate | 15 | $16,033 |
| Anastrozole | 532 | $7,962 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $41 | $3,004,426135 claims |
| PfizerIbrance, Inlyta, Eliquis | $453 | $1,369,739117 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $894 | $677,35654 claims |
| Johnson & JohnsonErleada | $1,129 | $644,48443 claims |
| MerckKeytruda | $763 | $585,78243 claims |
| Lilly USA, LLCVerzenio | $350 | $332,65822 claims |
| AbbVieSynthroid | $212 | $1,71529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Guayama
- Mirelis AcostaSan Juan$6.3M
- Hector Velez CortesPonce$3.1M
- Luis FloresSan Juan$2.3M
- Noridza Rivera RodriguezSan Juan$2.1M
- Adelba Torres-LopezSan Juan$1.9M
- Maria Garcia PallasCaguas$1.8M
- Karina Arocho-GonzalezHato Rey$1.1M
- Jose Lozada CostasSan Juan$934K
- Fernando CabanillasSan Juan$916K
- Mayra Rivera FigueroaRio Piedras$745K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.